Expression of high molecular weight cytokeratin—A novel feature of aggressive and innate hormone‐refractory prostatic adenocarcinoma

The study demonstrated HMWCK PAC to be a novel type of innate ADT-resistant PAC. Overexpression of HMWCK in PAC can be potentially used as a surrogate biomarker for aggressive and innate hormone-refractory PACs. The genetic alterations imply potential therapeutic implications of PI3K/MAPK inhibitors in the treatment of these deadly diseases.